blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1286665

EP1286665 - TREATMENT REGIMEN OF INTRAVENOUS ZOLEDRONATE FOR THE TREATMENT OF BONE METABOLISM DISEASES [Right-click to bookmark this link]
Former [2003/10]USE OF ZOLENDRONATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BONE METABOLISM DISEASES
[2013/08]
StatusPatent revoked
Status updated on  24.10.2014
Database last updated on 30.09.2024
Most recent event   Tooltip03.06.2022Lapse of the patent in a contracting state
New state(s): TR		published on 06.07.2022  [2022/27]
Applicant(s)For:BE  CH  CY  DE  DK  ES  FI  FR  GB  GR  IE  IT  LI  LU  MC  NL  PT  SE  TR 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
[2013/16]
Former [2003/11]For:BE  CH  CY  DE  DK  ES  FI  FR  GB  GR  IE  IT  LI  LU  MC  NL  PT  SE  TR 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
Former [2003/10]For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Inventor(s)01 / SEAMAN, John, J.
118 Rolling Hill Court
New Hope, PA 18938 / US
02 / GALLI, Bruno
Liestalerstrasse 28 D
4411 Seltisberg / CH
03 / SCHRAN, Horst
17 Junard Drive
Morristown, NJ 07960 / US
 [2013/10]
Former [2003/10]01 / SEAMAN, John, J.
118 Rolling Hill Court
New Hope, PA 18938 / US
02 / SIGG, Juergen
Karl-Arzet-Weg 25
79540 Loerrach / DE
03 / SCHRAN, Horst
17 Junard Drive
Morristown, NJ 07960 / US
Representative(s)Kristl, Jernej, et al
Novartis Pharma AG
Patent Department
4002 Basel / CH
[2013/19]
Former [2013/03]Trösch, Dominique, et al
Henkel, Breuer & Partner
Patentanwälte
Erika-Mann-Straße 23
80636 München / DE
Former [2003/10]Gros, Florent, et al
Novartis AG
4002 Basel / CH
Application number, filing date01935167.509.05.2001
[2003/10]
WO2001US14886
Priority number, dateGB2000001220919.05.2000         Original published format: GB 0012209
[2003/10]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO0189494
Date:29.11.2001
Language:EN
[2001/48]
Type: A2 Application without search report 
No.:EP1286665
Date:05.03.2003
Language:EN
The application published by WIPO in one of the EPO official languages on 29.11.2001 takes the place of the publication of the European patent application.
[2003/10]
Type: B1 Patent specification 
No.:EP1286665
Date:17.04.2013
Language:EN
[2013/16]
Search report(s)International search report - published on:EP23.05.2002
ClassificationIPC:A61K31/662, A61K9/08, A61P19/08, A61P35/00, // A61K9/19
[2013/08]
CPC:
A61K31/662 (EP); A61K47/12 (EP); A61K9/0019 (EP);
A61K9/08 (EP); A61P19/00 (EP); A61P19/08 (EP);
A61P3/14 (EP); A61P35/00 (EP); A61P35/04 (EP);
A61K9/19 (EP) (-)
Former IPC [2003/10]A61K31/00
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2003/10]
TitleGerman:BEHANDLUNGSSCHEMA VON ZOLEDRONAT ZUR BEHANDLUNG VON ERKRANKUNGEN DES KNOCHENMETABOLISMUS[2013/08]
English:TREATMENT REGIMEN OF INTRAVENOUS ZOLEDRONATE FOR THE TREATMENT OF BONE METABOLISM DISEASES[2013/08]
French:SCHEMA DE TRAITEMENT DU ZOLEDRONATE POUR LES MALADIES DE METABOLISME OSSEUX[2013/08]
Former [2003/10]VERWENDUNG VON ZOLENDRONATE ZUR HERSTELLUNG EINES MEDIKAMENTES ZUR BEHANDLUNG VON ERKRANKUNGEN DES KNOCHENMETABOLISMUS
Former [2003/10]USE OF ZOLENDRONATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BONE METABOLISM DISEASES
Former [2003/10]PROCEDE D'ADMINISTRATION D'UN BISPHOSPHONATE
Entry into regional phase19.12.2002National basic fee paid 
19.12.2002Designation fee(s) paid 
19.12.2002Examination fee paid 
Examination procedure12.12.2001Request for preliminary examination filed
International Preliminary Examining Authority: EP
11.11.2002Amendment by applicant (claims and/or description)
19.12.2002Examination requested  [2003/10]
13.11.2006Despatch of a communication from the examining division (Time limit: M06)
29.06.2007Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
04.09.2007Reply to a communication from the examining division
15.07.2011Despatch of a communication from the examining division (Time limit: M06)
24.01.2012Reply to a communication from the examining division
10.03.2012Observations by third parties
22.09.2012Observations by third parties
10.12.2012Observations by third parties
14.12.2012Observations by third parties
09.01.2013Date of oral proceedings
28.01.2013Minutes of oral proceedings despatched
04.02.2013Observations by third parties
08.02.2013Communication of intention to grant the patent
08.02.2013Observations by third parties
11.02.2013Fee for grant paid
11.02.2013Fee for publishing/printing paid
14.02.2013Observations by third parties
20.02.2013Observations by third parties
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.11.2006
Opposition(s)Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Fünf Höfe / Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013  17.05.2013  ADMISSIBLE
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP
Maximiliansplatz 22
80333 München / DE
 05  15.05.2013  11.06.2013  ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
 06  24.06.2013  04.07.2013  ADMISSIBLE
Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH
Door 8-2-337, Road No 3, Banjara Hills/
Kobelweg 95
Hyderabad-500034
Andhra Pradesh/86156 Augsburg DE / IN
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 07  27.06.2013  04.07.2013  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg, et al, et al
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 08  14.08.2013  19.09.2013  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Krömer-Strasse 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH, et al, et al
Patent Department
Borkenberg 14
61440 Oberursel / DE
 09  12.09.2013  19.09.2013  ADMISSIBLE
Hikma Pharma GmbH
Lochhamer Schlag 17
82166 Gräfelfing / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
 10  25.09.2013  01.10.2013  ADMISSIBLE
PFIZER LIMITED
Ramsgate Road
SANDWICH, KENT CT13 9NJ / GB
Opponent's representative
Pfizer, et al, et al
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 11  18.11.2013  26.11.2013  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 12  30.12.2013  14.01.2014  ADMISSIBLE
Genericon Pharma Gesellschaft m.b.H.
Hafnerstrasse 211
8054 Graz / AT
Opponent's representative
Keschmann, Marc
Haffner und Keschmann Patentanwälte GmbH
Schottengasse 3a
1010 Wien / AT
 13  09.01.2014  22.01.2014  ADMISSIBLE
Sanovel IIaç San. ve Tic. A.S.
Balabandere Cad. Ilaç Sanayi Yolu
No: 14 Istinye-Sariyer 34460
Istanbul / TR
Opponent's representative
von Uexküll - Güldenband, Alexa
Vossius & Partner
Siebertstrasse 4
81675 München / DE
 14  14.01.2014  24.01.2014  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Santamaria Gamez, Antoni
Accord Healthcare SLU
World Trade Center
Moll Barcelona s/n
Edifici Est, 6th Floor
08039 Barcelona / ES
 15  14.01.2014  24.01.2014  ADMISSIBLE
Synthon B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
Prins, Hendrik Willem
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
 16  16.01.2014  11.02.2014  ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 Colombes Cedex / FR
Opponent's representative
Casalonga, et al, et al
Casalonga & Partners
Bayerstraße 71/73
80335 München / DE
 17  17.01.2014  28.01.2014  ADMISSIBLE
Taylor Wessing LLP
5 New Street Square
London EC4A 3TW / GB
 [N/P]
Former [2014/09]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013  17.05.2013  ADMISSIBLE
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP
Maximiliansplatz 22
80333 München / DE
 05  15.05.2013  11.06.2013  ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
 06  24.06.2013  04.07.2013  ADMISSIBLE
Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH
Door 8-2-337, Road No 3, Banjara Hills/
Kobelweg 95
Hyderabad-500034
Andhra Pradesh/86156 Augsburg DE / IN
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 07  27.06.2013  04.07.2013  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
UEXKÜLL & STOLBERG, et al, et al
Patentanwälte
Beselerstrasse 4
22607 Hamburg / DE
 08  14.08.2013  19.09.2013  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Krömer-Strasse 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH, et al, et al
Patent Department
Borkenberg 14
61440 Oberursel / DE
 09  12.09.2013  19.09.2013  ADMISSIBLE
Hikma Pharma GmbH
Lochhamer Schlag 17
82166 Gräfelfing / DE
Opponent's representative
Grund, Martin
Grund
Intellectual Property Group
Postfach 44 05 16
80754 München / DE
 10  25.09.2013  01.10.2013  ADMISSIBLE
PFIZER LIMITED
Ramsgate Road
SANDWICH, KENT CT13 9NJ / GB
Opponent's representative
Pfizer, et al, et al
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 11  18.11.2013  26.11.2013  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 12  30.12.2013  14.01.2014  ADMISSIBLE
Genericon Pharma Gesellschaft m.b.H.
Hafnerstrasse 211
8054 Graz / AT
Opponent's representative
Keschmann, Marc
Haffner und Keschmann Patentanwälte GmbH
Schottengasse 3a
1010 Wien / AT
 13  09.01.2014  22.01.2014  ADMISSIBLE
Sanovel IIaç San. ve Tic. A.S.
Balabandere Cad. Ilaç Sanayi Yolu
No: 14 Istinye-Sariyer 34460
Istanbul / TR
Opponent's representative
von Uexküll - Güldenband, Alexa
Vossius & Partner Siebertstrasse 4
81675 München / DE
 14  14.01.2014    ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Santamaria Gamez, Antoni
Accord Healthcare SLU
World Trade Center
Moll Barcelona s/n
Edifici Est, 6th Floor
08039 Barcelona / ES
 15  14.01.2014    ADMISSIBLE
Synthon B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
Prins, Hendrik Willem
Arnold & Siedsma Sweelinckplein 1
2517 GK The Hague / NL
 16  16.01.2014    ADMISSIBLE
BIOGARAN
15 Boulevard Charles de Gaulle
92707 Colombes Cedex / FR
Opponent's representative
Casalonga, et al, et al
Casalonga & Partners
Bayerstraße 71/73
80335 München / DE
 17  17.01.2014    ADMISSIBLE
Taylor Wessing LLP
5 New Street Square
London EC4A 3TW / GB
Former [2014/08]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013  17.05.2013  ADMISSIBLE
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP
Maximiliansplatz 22
80333 München / DE
 05  15.05.2013  11.06.2013  ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
 06  24.06.2013  04.07.2013  ADMISSIBLE
Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH
Door 8-2-337, Road No 3, Banjara Hills/
Kobelweg 95
Hyderabad-500034
Andhra Pradesh/86156 Augsburg DE / IN
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 07  27.06.2013  04.07.2013  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
UEXKÜLL & STOLBERG, et al, et al
Patentanwälte
Beselerstrasse 4
22607 Hamburg / DE
 08  14.08.2013  19.09.2013  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Krömer-Strasse 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH, et al, et al
Patent Department
Borkenberg 14
61440 Oberursel / DE
 09  12.09.2013  19.09.2013  ADMISSIBLE
Hikma Pharma GmbH
Lochhamer Schlag 17
82166 Gräfelfing / DE
Opponent's representative
Grund, Martin
Grund
Intellectual Property Group
Postfach 44 05 16
80754 München / DE
 10  25.09.2013  01.10.2013  ADMISSIBLE
PFIZER LIMITED
Ramsgate Road
SANDWICH, KENT CT13 9NJ / GB
Opponent's representative
Pfizer, et al, et al
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 11  18.11.2013  26.11.2013  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 12  30.12.2013  14.01.2014  ADMISSIBLE
Genericon Pharma Gesellschaft m.b.H.
Hafnerstrasse 211
8054 Graz / AT
Opponent's representative
Keschmann, Marc
Haffner und Keschmann Patentanwälte GmbH
Schottengasse 3a
1010 Wien / AT
 13  09.01.2014    ADMISSIBLE
Sanovel IIaç San. ve Tic. A.S.
Balabandere Cad. Ilaç Sanayi Yolu
No: 14 Istinye-Sariyer 34460
Istanbul / TR
Opponent's representative
von Uexküll - Güldenband, Alexa
Vossius & Partner Siebertstrasse 4
81675 München / DE
 14  14.01.2014   
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Santamaria Gamez, Antoni
Accord Healthcare SLU
World Trade Center
Moll Barcelona s/n
Edifici Est, 6th Floor
08039 Barcelona / ES
 15  14.01.2014   
Synthon B.V.
Microweg 22
6545 CM Nijmegen / NL
Opponent's representative
Prins, Hendrik Willem
Arnold & Siedsma Sweelinckplein 1
2517 GK The Hague / NL
Former [2013/52]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013  17.05.2013  ADMISSIBLE
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP Pacellistraße 14
80333 München / DE
 05  15.05.2013  11.06.2013  ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
 06  24.06.2013  04.07.2013  ADMISSIBLE
Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH
Door 8-2-337, Road No 3, Banjara Hills/
Kobelweg 95
Hyderabad-500034
Andhra Pradesh/86156 Augsburg DE / IN
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 07  27.06.2013  04.07.2013  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
UEXKÜLL & STOLBERG, et al, et al
Patentanwälte
Beselerstrasse 4
22607 Hamburg / DE
 08  14.08.2013  19.09.2013  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Krömer-Strasse 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH, et al, et al
Patent Department
Borkenberg 14
61440 Oberursel / DE
 09  12.09.2013  19.09.2013  ADMISSIBLE
Hikma Pharma GmbH
Lochhamer Schlag 17
82166 Gräfelfing / DE
Opponent's representative
Grund, Martin
Grund
Intellectual Property Group
Postfach 44 05 16
80754 München / DE
 10  25.09.2013  01.10.2013  ADMISSIBLE
PFIZER LIMITED
Ramsgate Road
SANDWICH, KENT CT13 9NJ / GB
Opponent's representative
Pfizer, et al, et al
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 11  18.11.2013    ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
Former [2013/45]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013  17.05.2013  ADMISSIBLE
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP Pacellistraße 14
80333 München / DE
 05  15.05.2013  11.06.2013  ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
 06  24.06.2013  04.07.2013  ADMISSIBLE
Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH
Door 8-2-337, Road No 3, Banjara Hills/
Kobelweg 95
Hyderabad-500034
Andhra Pradesh/86156 Augsburg DE / IN
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 07  27.06.2013  04.07.2013  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
UEXKÜLL & STOLBERG, et al, et al
Patentanwälte
Beselerstrasse 4
22607 Hamburg / DE
 08  14.08.2013  19.09.2013  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Krömer-Strasse 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH, et al, et al
Patent Department
Borkenberg 14
61440 Oberursel / DE
 09  12.09.2013  19.09.2013  ADMISSIBLE
Hikma Pharma GmbH
Lochhamer Schlag 17
82166 Gräfelfing / DE
Opponent's representative
Grund, Martin
Grund
Intellectual Property Group
Postfach 44 05 16
80754 München / DE
 10  25.09.2013  01.10.2013  ADMISSIBLE
PFIZER LIMITED
Ramsgate Road
SANDWICH, KENT CT13 9NJ / GB
Opponent's representative
Pfizer, et al, et al
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
Former [2013/43]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013  17.05.2013  ADMISSIBLE
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP Pacellistraße 14
80333 München / DE
 05  15.05.2013  11.06.2013  ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
 06  24.06.2013  04.07.2013  ADMISSIBLE
Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH
Door 8-2-337, Road No 3, Banjara Hills/
Kobelweg 95
Hyderabad-500034
Andhra Pradesh/86156 Augsburg DE / IN
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 07  27.06.2013  04.07.2013  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
UEXKÜLL & STOLBERG, et al, et al
Patentanwälte
Beselerstrasse 4
22607 Hamburg / DE
 08  14.08.2013  19.09.2013  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Krömer-Strasse 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH, et al, et al
Patent Department
Borkenberg 14
61440 Oberursel / DE
 09  12.09.2013  19.09.2013  ADMISSIBLE
Hikma Pharma GmbH
Lochhamer Schlag 17
82166 Gräfelfing / DE
Opponent's representative
Grund, Martin
Grund
Intellectual Property Group
Postfach 44 05 16
80754 München / DE
Former [2013/39]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013  17.05.2013  ADMISSIBLE
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP Pacellistraße 14
80333 München / DE
 05  15.05.2013  11.06.2013  ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
 06  24.06.2013  04.07.2013  ADMISSIBLE
Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH
Door 8-2-337, Road No 3, Banjara Hills/
Kobelweg 95
Hyderabad-500034
Andhra Pradesh/86156 Augsburg DE / IN
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 07  27.06.2013  04.07.2013  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
UEXKÜLL & STOLBERG, et al, et al
Patentanwälte
Beselerstrasse 4
22607 Hamburg / DE
 08  14.08.2013    ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Krömer-Strasse 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH, et al, et al
Patent Department
Borkenberg 14
61440 Oberursel / DE
Former [2013/32]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013  17.05.2013  ADMISSIBLE
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP Pacellistraße 14
80333 München / DE
 05  15.05.2013  11.06.2013  ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
 06  24.06.2013  04.07.2013  ADMISSIBLE
Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH
Door 8-2-337, Road No 3, Banjara Hills/
Kobelweg 95
Hyderabad-500034
Andhra Pradesh/86156 Augsburg DE / IN
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 07  27.06.2013  04.07.2013  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
UEXKÜLL & STOLBERG, et al, et al
Patentanwälte
Beselerstrasse 4
22607 Hamburg / DE
Former [2013/31]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013  17.05.2013  ADMISSIBLE
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP Pacellistraße 14
80333 München / DE
 05  15.05.2013  11.06.2013  ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
 06  24.06.2013    ADMISSIBLE
Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH
Door 8-2-337, Road No 3, Banjara Hills/
Kobelweg 95
Hyderabad-500034
Andhra Pradesh/86156 Augsburg DE / IN
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
Former [2013/25]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013  15.05.2013  ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
 04  10.05.2013   
Actavis Group Ptc Ehf
Reykjavikurvegi 76-78
220 Hafnarfjörour / IS
Opponent's representative
Alt, Michael
Bird & Bird LLP Pacellistraße 14
80333 München / DE
 05  15.05.2013    ADMISSIBLE
CHEMI SPA
Via dei Lavoratori 54
20092 Cinisello Balsamo, Milano / IT
Opponent's representative
Longoni, Alessandra
AL & Partners Srl Via C. Colombo ang. Via Appiani (Corte del Cotone)
20831 Seregno (MB) / IT
Former [2013/24]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013  29.04.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 03  03.05.2013    ADMISSIBLE
hameln rds gmbh
Langes Feld 13
31789 Hameln / DE
Former [2013/22]
Opponent(s)01  17.04.2013  23.04.2013  ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
 02  24.04.2013    ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Friedrich, Rainer
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
Former [2013/21]
Opponent(s)01  17.04.2013    ADMISSIBLE
Generics [UK] Limited
(trading as Mylan)
Albany Gate
Darkes Lane
Potters Bar
Hertfordshire EN6 1AG / GB
Opponent's representative
Gillard, Richard Edward
Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA / GB
04.03.2014Invitation to proprietor to file observations on the notice of opposition
07.07.2014Despatch of communication that the patent will be revoked
17.07.2014Legal effect of revocation of patent [2014/48]
Request for further processing for:04.09.2007Request for further processing filed
04.09.2007Full payment received (date of receipt of payment)
Request granted
18.09.2007Decision despatched
Fees paidRenewal fee
02.06.2003Renewal fee patent year 03
01.06.2004Renewal fee patent year 04
31.05.2005Renewal fee patent year 05
31.05.2006Renewal fee patent year 06
31.05.2007Renewal fee patent year 07
28.03.2008Renewal fee patent year 08
02.06.2009Renewal fee patent year 09
31.03.2010Renewal fee patent year 10
11.05.2011Renewal fee patent year 11
30.03.2012Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCH17.04.2013
CY17.04.2013
DK17.04.2013
FI17.04.2013
LI17.04.2013
MC17.04.2013
NL17.04.2013
SE17.04.2013
TR17.04.2013
IE09.05.2013
LU09.05.2013
GB17.07.2013
PT19.08.2013
AT09.05.2014
IT09.05.2014
ES10.05.2014
[2022/27]
Former [2020/33]CH17.04.2013
CY17.04.2013
DK17.04.2013
FI17.04.2013
LI17.04.2013
MC17.04.2013
NL17.04.2013
SE17.04.2013
IE09.05.2013
LU09.05.2013
GB17.07.2013
PT19.08.2013
AT09.05.2014
IT09.05.2014
ES10.05.2014
Former [2015/34]CH17.04.2013
CY17.04.2013
DK17.04.2013
FI17.04.2013
LI17.04.2013
MC17.04.2013
NL17.04.2013
SE17.04.2013
IE09.05.2013
LU09.05.2013
GB17.07.2013
PT19.08.2013
AT09.05.2014
IT09.05.2014
Former [2015/23]CH17.04.2013
CY17.04.2013
DK17.04.2013
FI17.04.2013
LI17.04.2013
MC17.04.2013
NL17.04.2013
SE17.04.2013
IE09.05.2013
GB17.07.2013
PT19.08.2013
AT09.05.2014
IT09.05.2014
Former [2015/12]CH17.04.2013
CY17.04.2013
DK17.04.2013
FI17.04.2013
LI17.04.2013
MC17.04.2013
NL17.04.2013
SE17.04.2013
IE09.05.2013
GB17.07.2013
PT19.08.2013
AT09.05.2014
Former [2015/08]CH17.04.2013
CY17.04.2013
DK17.04.2013
FI17.04.2013
LI17.04.2013
MC17.04.2013
NL17.04.2013
SE17.04.2013
IE09.05.2013
GB17.07.2013
PT19.08.2013
Former [2014/21]CY17.04.2013
DK17.04.2013
FI17.04.2013
MC17.04.2013
NL17.04.2013
SE17.04.2013
IE09.05.2013
GB17.07.2013
PT19.08.2013
Former [2014/20]CY17.04.2013
DK17.04.2013
FI17.04.2013
MC17.04.2013
NL17.04.2013
SE17.04.2013
IE09.05.2013
PT19.08.2013
Former [2014/14]CY17.04.2013
DK17.04.2013
FI17.04.2013
MC17.04.2013
NL17.04.2013
SE17.04.2013
PT19.08.2013
Former [2014/09]CY17.04.2013
DK17.04.2013
FI17.04.2013
MC17.04.2013
SE17.04.2013
PT19.08.2013
Former [2014/08]CY17.04.2013
FI17.04.2013
MC17.04.2013
SE17.04.2013
PT19.08.2013
Former [2013/52]CY17.04.2013
FI17.04.2013
SE17.04.2013
PT19.08.2013
Former [2013/49]FI17.04.2013
SE17.04.2013
PT19.08.2013
Former [2013/47]PT19.08.2013
Cited inInternational search[PX]  - BERENSON J R ET AL, "A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.", CLINICAL CANCER RESEARCH, (2001 MAR) 7 (3) 478-85., XP001036868 [PX] 1-10 * abstract * * page 478, column 2, line 7 * * page 480, column 2, line 5 *
 [PXY]  - BERENSON JAMES R ET AL, "Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study.", CANCER, (20010401), vol. 91, no. 7, ISSN 0008-543X, pages 1191 - 1200, XP001036871 [PX] 1-5 * abstract * * page 1191, column 2, line 37 * * page 1192, column 2, lines 45,46 * [Y] 6-10

DOI:   http://dx.doi.org/10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0
 [XY]  - BODY J J, "Clinical research update: Zoledronate.", CANCER, (1997), vol. 80, no. 8 SUPPL., ISSN 0008-543X, pages 1699 - 1701, XP001037214 [X] 1-10 * abstract * * page 1700, column 2, line 2 * * page 1701, column 1, line 23 * * page 1701, column 2, lines 22-29 * [Y] 6-10

DOI:   http://dx.doi.org/10.1002/(SICI)1097-0142(19971015)80:8+<1699::AID-CNCR23>3.0.CO;2-U
 [XY]  - LIPTON A ET AL, "Phase II trial of zoledronate vs. pamidronate in multiple myeloma and breast cancer.", CANCER INVESTIGATION., XVII Symposium of the Chemotherapy Foundation: Innovative Cancer Therapy for Tomorrow.;New York, NY, USA; November 03-06, 1999, (2000), vol. 18, no. SUPPL. 1, ISSN 0735-7907, pages 68 - 69, XP001036876 [X] 1,2,4,5 * abstract * [Y] 6-10
 [Y]  - BUCKLER H ET AL, "Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study.", BONE (NEW YORK), International Symposium of the 25th Anniversary of the National Association for the Relief of Paget's Disease;Oxford, England, UK; July 15-17, 1998, (199905), vol. 24, no. 5 SUPPL., ISSN 8756-3282, pages 81S - 85S, XP001036896 [Y] 6-10 * page 82S, column 1, line 18 *

DOI:   http://dx.doi.org/10.1016/S8756-3282(99)00071-X
Examination   - Publication of Swiss marketing approval for Zometa® 4 mg, Lyophilisat in the IKS Monatsbericht 11/2000
    - Summary of Product Characteristics for Zometa® by Novartis
    - Product monograph for Zoledronate Disodium (Zometa) in Drugs of the Future, March 2000, 25(3), 259-268
    - GREEN J R ET AL, "Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models.", PHARMACOLOGY & TOXICOLOGY MAY 1997, (199705), vol. 80, no. 5, ISSN 0901-9928, pages 225 - 230
    - KANIS J A ET AL, "Effects of intravenous etidronate disodium on skeletal and calcium metabolism.", THE AMERICAN JOURNAL OF MEDICINE 23 FEB 1987, (19870223), vol. 82, no. 2A, ISSN 0002-9343, pages 55 - 70
    - MIAN M ET AL, "Tolerability and safety of clodronate therapy in bone diseases.", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH 1991, (1991), vol. 11, no. 2, ISSN 0251-1649, pages 107 - 114
    - MAJOR P ET AL, "Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 15 JAN 2001, (20010115), vol. 19, no. 2, ISSN 0732-183X, pages 558 - 567
    - NAKASHIMA L., "Guidelines for the treatment of hypercalcemiaassociated with malignancy", J. ONCOL. PHARM. PRACTICE, (1997), vol. 3, no. 1, pages 31 - 37
    - Affidavit of Dr. Horst Schran filed with the USPTO in 24.04.2006 during the prosecution of the equivalent US patent application US2004/0014724-A1
    - Berenson et al; Population pharmacokinetics (PK) of Zometa, 2000, Proceedings of ASCO, Vol. 19, Clinical Pharmacology, 209a, No. 814
    - BERENSON J R, "Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.", SEMINARS IN ONCOLOGY APR 2001, (200104), vol. 28, no. 2 Suppl 6, ISSN 0093-7754, pages 25 - 34
    - Fleisch; Bisphosphonates in bone disease, 1997, third edition, p.152.
    - ROSEN LEE S ET AL, "Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.", CANCER 15 OCT 2003, (20031015), vol. 98, no. 8, ISSN 0008-543X, pages 1735 - 1744
otherUS2004014724
    - GREEN J.R. ET AL, "RENAL TOLERABILITY PROFILE OF NOVEL, POTENT BISPHOSPHONATES IN TWO SHORT-TERM RAT MODELS", PHARMACOLOGY AND TOXICOLOGY, (19970101), vol. 80, no. 5, pages 225 - 230, XP001036879

DOI:   http://dx.doi.org/10.1111/j.1600-0773.1997.tb01964.x
    - ANONYMOUS, "Summary of Product Characteristics for Zometa(R)", NOVARTIS, (200005), pages 1 - 3, XP003026145
    - SORBERA L.A. ET AL, "ZOLEDRONATE DISODIUM TREATMENT OF TUMOR-INDUCED HYPERCALCEMIA ANGIOGENESIS INHIBITOR", DRUGS OF THE FUTURE, (200003), vol. 25, no. 3, pages 259 - 268, XP008010716

DOI:   http://dx.doi.org/10.1358/dof.2000.025.03.569207
    - KANIS J.A. ET AL, "Effects of intravenous etidronate disodium on skeletal and calcium metabolism", AMER. J. MED. SUPPL. 2A, (19870223), vol. 82, pages 55 - 70, XP023305069

DOI:   http://dx.doi.org/10.1016/0002-9343(87)90488-8
    - MIAN M. ET AL, "Tolerability and safety of clodronate therapy in bone diseases.", INT. J. CLIN. PHARM. RES., (1991), vol. XI, no. 2, pages 107 - 114, XP003029281
    - BERENSON J.R. ET AL, "A PHASE I DOSE-RANGING TRIAL OF MONTHLY INFUSIONS OF ZOLEDRONIC ACID FOR THE TREATMENT OF OSTEOLYTIC BONE METASTASES", CLIN. CANCER RES., (200103), vol. 7, pages 478 - 485, XP001036868
    - BERENSON J.R. ET AL, "ZOLEDRONIC ACID REDUCES SKELETAL-RELATED EVENTS IN PATIENTS WITH OSTEOLYTIC METASTASES: A DOUBLE-BLIND, RANDOMIZED DOSE-RESPONSE STUDY", CANCER, (20010401), vol. 91, no. 7, pages 1191 - 1200, XP001036871

DOI:   http://dx.doi.org/10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0
    - BODY J.J., "CLINICAL RESEARCH UPDATE: ZOLEDRONATE", CANCER SUPPL, (19971015), vol. 80, no. 8, pages 1699 - 1701, XP001148496

DOI:   http://dx.doi.org/10.1002/(SICI)1097-0142(19971015)80:8+<1699::AID-CNCR23>3.0.CO;2-U
    - LIPTON A. ET AL, "PHASE II TRIAL OF ZOLEDRONATE VS. PAMIDRONATE IN MULTIPLE MYELOMA AND BREAST CANCER.", CANCER INVESTIGATION, SUPPL. 1, (2000), vol. 18, pages 68 - 69, XP001036876
    - BUCKLER H. ET AL, "SINGLE INFUSION OF ZOLEDRONATE IN PAGET'S DISEASE OF BONE: A PLACEBO-CONTROLLED,DOSE-RANGING STUDY", BONE, SUPPLEMENT, (1999), vol. 24, no. 5, pages 81S - 85S, XP001026721

DOI:   http://dx.doi.org/10.1016/S8756-3282(99)00071-X
    - MAJOR P. ET AL, "ZOLEDRONIC ACID IS SUPERIOR TO PAMIDRONATE IN THE TREATMENT OF HYPERCALCEMIA OF MALIGNANCY: A POOLED ANALYSIS OF TWO RANDOMIZED, CONTROLLED CLINICAL TRIALS", JOURNAL OF CLINICAL ONCOLOGY, (20010115), vol. 19, no. 2, pages 558 - 567, XP001034173
    - NAKASHIMA L., "Guidelines for the treatment of hypercalcemia associated with malignancy", J. ONCOL. PHARM. PRACTICE, (1997), vol. 3, no. 1, pages 31 - 37, XP003029282

DOI:   http://dx.doi.org/10.1177/107815529700300105
    - BERENSON J.R. ET AL, "Population pharmacokinetics (PK) of Zometa (abstr.nr. 814)", PROCEEDINGS OF ASCO, (20000520), vol. 19, page 209, XP003029283
    - BERENSON J.R., "Zoledronic acid in cancer patients with bone metastases: Results of phase I and II trials.", SEMINARS IN ONCOLOGY, SUPPL. 6, (200104), vol. 28, no. 2, pages 25 - 34, XP003029284
    - FLEISCH ET AL, BISPHOSPHONATES IN BONE DISEASE, THIRD EDITION, (1997), page 152, XP003029285
    - ADAMI S. ET AL, "Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol", J. BONE MINER. RES., (2000), vol. 15, no. 3, pages 599 - 604, XP003029620

DOI:   http://dx.doi.org/10.1359/jbmr.2000.15.3.599
    - ADAMI S. ET AL, "diverse effects of bisphosphonates. A comparative review.", DRUG SAF., (199603), vol. 14, no. 3, pages 158 - 170, XP003029621

DOI:   http://dx.doi.org/10.2165/00002018-199614030-00003
    - FLEISCH H.A., "BISPHOSPHONATES: PRECLINICAL ASPECTS AND USE IN OSTEOPOROSIS", ANN. MED., (1997), vol. 29, pages 55 - 62, XP000904875
    - ZOMETA, FDA CLINICAL BRIEFING DOCUMENT FOR THE ONCOLOGIC DRUGS ADVISORY COMMITTEE, pages 1 - 3, 14, XP003029622
    - OFFICIAL JOURNAL OF THE EUROPEAN COMMUNITIES., (20010427), pages C 127/2 - C 127/6, XP003029623
    - ZOMETA., SUMMARY OF PRODUCT CHARACTERISTICS, (200103), pages 1 - 42, XP003029624
    - "I.V. therapy", LEWIS J.A., ILLUSTRATED MANUAL of NURSING PRACTICE, Second Edition, pages 99 - 117, XP003029625
    - "Infusion Devices", MALLETT J. ET AL, The Royal Marsden Hospital Manual of Clinical Nursing Procedures, Fifth Edition, (2000), pages 319 - 333, XP003029626
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.